Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 17Stomach Neoplasms 5Rectal Neoplasms 2Colonic Neoplasms 2Advanced Colorectal Carcinoma 2Unresectable Metastatic Colorectal Cancer 1TAS 102 1Sarcoma 1Patients With Advanced Metastatic Colorectal Cancer 1Pancreatic Neoplasms 1Metastasis Colorectal Cancer 1Locally Advanced Rectal Cancer 1HER2-positive Gastric Cancer 1Fruquintinib 1Esophageal Squamous Cell Carcinoma 1Colorectal Adenocarcinoma 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Biliary Tract Adenocarcinoma 1Advanced Pancreatic Carcinoma 1

Interventions

HMPL-013 1Drug Therapy 1Capecitabine 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Unresectable Metastatic Colorectal Cancer × HMPL-013 × Clear all
NCT04866108 2022-08-18

A Phase II Study of Fruquintinib Combined With Capecitabine as First-line Treatment for Advanced Metastatic Colorectal Cancer Unsuitable for Intravenous Chemotherapy

Beijing Friendship Hospital

Phase 2 Unknown
49 enrolled
Gastrointestinal

Unresectable Metastatic Colorectal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡